In vivo stabilization of mutant human transthyretin in transgenic mice

Amyloid

Volumn 14, Issue 3, 2007, Pages 227-236

  Tagoe, Clement E ^a   Reixach, Natàlia ^b   Friske, Linsey ^b   Mustra, David ^b   French, David ^b   Gallo, Gloria ^a   Buxbaum, Joel N ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Amyloidosis; Diflunisal; FAP; Heterotetramers; Transgenics; Transthyretin

Indexed keywords

DIFLUNISAL; PREALBUMIN;

AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CONTROLLED STUDY; GENE SEQUENCE; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; TRANSGENE;

AMYLOID; AMYLOIDOSIS; ANIMALS; FEMALE; HUMANS; KIDNEY; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, TRANSGENIC; PREALBUMIN; PROTEIN STRUCTURE, QUATERNARY; TISSUE DISTRIBUTION; TRANSGENES;

EID: 34547890291     PISSN: 13506129     EISSN: 17442818     Source Type: Journal    
DOI: 10.1080/13506120701464396     Document Type: Article

References (29)

1. Buxbaum JN. The Amyloidoses. In: Hochberg SSWWSC, editor. Rheumatology. London: Elsevier; 2005. pp 2015-2026.
2. Kelly JW, Colon W, Lai Z, Lashuel HA, McCulloch J, McCutchen SL, Miroy GJ, Peterson SA. Transthyretin quaternary and tertiary structural changes facilitate misassembly into amyloid. Adv Protein Chem 1997;50:161-181.
3. Jacobson DR, McFarlin DE, Kane I, Buxbaum JN. Transthyretin Pro55, a variant associated with early-onset, aggressive, diffuse amyloidosis with cardiac and neurologic involvement. Hum Genet 1992;89:353-356.
4. Lashuel HA, Wurth C, Woo L, Kelly JW. The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions. Biochemistry 1999;38:13560-13573.
5. McCutchen SL, Lai Z, Miroy GJ, Kelly JW, Colon W. Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease. Biochemistry 1995;34:13527-13536.
6. McCutchen SL, Colon W, Kelly JW. Transthyretin mutation Leu-55-Pro significantly alters tetramer stability and increases amyloidogenicity. Biochemistry 1993;32:12119-12127.
7. Teng MH, Gallo G, Buxbaum J. Is an amyloidogenic substrate enough? Transgenic mice producing human TTR Pro55 do not develop amyloid. Neuromusc Disord 1996;6(Suppl. 1):S30.
8. Teng MH, Yin JY, Vidal R, Ghiso J, Kumar A, Rabenou R, Shah A, Jacobson DR, Tagoe C, Gallo G, Buxbaum J. Amyloid and nonfibrillar deposits in mice transgenic for wild-type human transthyretin: a possible model for senile systemic amyloidosis. Lab Invest 2001;81:385-396.
9. Episkopou V, Maeda S, Nishiguchi S, Shimada K, Gaitanaris GA, Gottesman ME, Robertson EJ. Disruption of the transthyretin gene results in mice with depressed levels of plasma retinol and thyroid hormone. Proc Natl Acad Sci USA 1993;90:2375-2379.
10. Ritchie RF, Palomaki GE, Neveux LM, Navolotskaia O. Reference distributions for the negative acute-phase proteins, albumin, transferrin, and transthyretin: a comparison of a large cohort to the world's literature. J Clin Lab Anal 1999;13:280-286.
11. Vranckx R, Savu L, Maya M, Rouaze-Romet M, Nunez EA. Immunological quantitation of rat and mouse thyroxine-binding globulins. Ontogenesis and sex-dependence of the circulating levels of the thyroxine-binding globulins. Acta Endocrinol 1990;123:649-656.
12. Lipman RD, Gaillard ET, Harrison DE, Bronson RT. Husbandry factors and the prevalence of age-related amyloidosis in mice. Lab Anim Sci 1993;43:439-444.
13. Picken MM, Gallo GR, Frangione B. Amyloid enhancing factor and inflammatory reaction. Lab Invest 1990;63:586-587.
14. Reixach N, Deechongkit S, Jiang X, Kelly JW, Buxbaum JN. Tissue damage in the amyloidoses: transthyretin monomers and non-native oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci USA 2004;101:2817-2822.
15. Reixach N, Adamski-Werner SL, Kelly JW, Koziol J, Buxbaum JN. Cell based screening of inhibitors of transthyretin aggregation. Biochem Biophys Res Commun 2006;348:889-897.
16. Adamski-Werner SL, Palaninathan SK, Sacchettini JC, Kelly JW. Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. J Med Chem 2004;47:355-374.
17. Yan C, Costa RH, Darnell JE Jr, Chen JD, Van Dyke TA. Distinct positive and negative elements control the limited hepatocyte and choroid plexus expression of transthyretin in transgenic mice. EMBO J 1990;9:869-878.
18. Kohno K, Palha JA, Miyakawa K, Saraiva MJ, Ito S, Mabuchi T, Blaner WS, Iijima H, Tsukahara S, Episkopou V, Gottesman ME, Shimada K, Takahashi K, Yamamura K, Maeda S. Analysis of amyloid deposition in a transgenic mouse model of homozygous familial amyloidotic polyneuropathy. Am J Pathol 1997;150:1497-1508.
19. Takeda T, Hosokawa M, Higuchi K, Hosono M, Akiguchi I, Katoh H. A novel murine model of aging, Senescence-Accelerated Mouse (SAM). Arch Gerontol Geriatr 1994;19:185-192.
20. Sousa M, Fernandes R, Palha J, Taboada A, Vieira P, Saraiva M. Evidence for early cytotoxicity aggregates in transgenic mice for human transthyretin Leu55Pro. Am J Pathol 2002;161:1935-1948.
21. Sousa MM, Cardoso I, Fernandes R, Guimaraes A, Saraiva MJ. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am J Pathol 2001;159:1993-2000.
22. Skinner M, Connors LH, Rubinow A, Libbey C, Sipe JD, Cohen AS. Lowered prealbumin levels in patients with familial amyloid polyneuropathy (FAP) and their nonaffected but at risk relatives. Am J Med Sci 1985;289:17-21.
23. Benson MD, Dwulet FE. Prealbumin and retinol binding protein serum concentrations in the Indiana type hereditary amyloidosis. Arthritis Rheum 1983;26:1493-1498.
24. Kelly JW. The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr Opin Struct Biol 1998;8:101-106.
25. Hammarström P, Jiang X, Hurshman AR, Powers ET, Kelly JW. Sequence-dependent denaturation energetics: a major determinant in amyloid disease diversity. Proc Natl Acad Sci USA 2002;99(Suppl. 4):16427-16432.
26. Hammarstrom P, Schneider F, Kelly JW. Trans-suppression of misfolding in an amyloid disease. Science 2001;293:2459-2462.
27. Coelho T, Chorao R, Sousa A, Alves I, Torres MF, Saraiva MJM. Compound heterozygotes of transthyretin MET 30 and transthyretin MET 119 are protected from the devastating effects of familial amyloid polyneuropathy. Neuromusc Disord 1996;6(Suppl. 1):S20.
28. Schreiber G. The evolutionary and integrative roles of transthyretin in thyroid hormone homeostasis. J Endocrinol 2002;175:61-73.
29. Tojo K, Sekijima Y, Kelly JW, Ikeda SI. Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis. Neurosci Res 2006;56:441-449.